Droia Ventures is a specialized investor dedicated to making an impact and saving patient lives. We focus on investing in the most promising life science companies, particularly in the field of therapeutics for oncology and genetic diseases. Our goal is to support young drug development companies that utilize novel science and innovative approaches to bring about promising therapies for patients.

With our in-house team of drug development experts and biotech professionals, we actively accelerate the progress of our portfolio companies from their creation to clinical proof of concept. We take a hands-on approach, actively participating in our companies' development and even taking on interim roles within the companies to ensure they get off the ground faster. We only invest in companies that can go after previously unsolvable clinical problems through their technology platforms or scientific insights.

We prioritize companies that not only differentiate through innovation but also translate that innovation into clinical breakthroughs. Through our portfolio, we have invested in companies such as Accent Therapeutics, Actio Biosciences, Arcus Biosciences, and many more. The products and therapies developed by these companies target various diseases and medical conditions, such as epitranscriptomics, rare diseases, cancer, and neurodegenerative disorders.

At Droia Ventures, we are committed to building great drug development companies and making a difference in the lives of patients